Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma

Tumor-informed Signatera testing was feasible in predominantly HPV-negative HNSCC; post-treatment ctDNA positivity was associated with worse progression-free survival (HR 7.33).

Clin Cancer ResPubMed 38824449DOI 10.1158/1078-0432.CCR-24-0590